The emergence of compounds like copyright and Semaglutide signifies a significant shift in how we manage metabolic disorders. These new therapies belong to a class known as GLP-1 receptor agonists, which replicate the effects of a natural hormone that regulates blood sugar levels and hunger. First, developed for managing blood sugar, their effectiv